CN116390756A - 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 - Google Patents

抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 Download PDF

Info

Publication number
CN116390756A
CN116390756A CN202180071515.9A CN202180071515A CN116390756A CN 116390756 A CN116390756 A CN 116390756A CN 202180071515 A CN202180071515 A CN 202180071515A CN 116390756 A CN116390756 A CN 116390756A
Authority
CN
China
Prior art keywords
sma
patient
apilimumab
therapy
smn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180071515.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·诺米科斯
宋国臣
R·伊尔鲁宾诺
Y·奇恩格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stone Supply Co
Original Assignee
Stone Supply Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stone Supply Co filed Critical Stone Supply Co
Publication of CN116390756A publication Critical patent/CN116390756A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180071515.9A 2020-10-26 2021-10-25 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 Pending CN116390756A (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US63/105,850 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US63/106,172 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US63/200,955 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US63/201,157 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US63/202,317 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US63/202,372 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US63/202,900 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US63/260,725 2021-08-30
US202163261398P 2021-09-20 2021-09-20
US63/261,398 2021-09-20
PCT/US2021/056517 WO2022093724A1 (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
CN116390756A true CN116390756A (zh) 2023-07-04

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180071515.9A Pending CN116390756A (zh) 2020-10-26 2021-10-25 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途

Country Status (13)

Country Link
US (1) US20240002490A1 (https=)
EP (2) EP4729069A1 (https=)
JP (1) JP2023549455A (https=)
KR (1) KR20230095998A (https=)
CN (1) CN116390756A (https=)
AU (1) AU2021369471A1 (https=)
CA (1) CA3193909A1 (https=)
ES (1) ES3058087T3 (https=)
IL (1) IL302132A (https=)
MX (1) MX2023004763A (https=)
PL (1) PL4232151T3 (https=)
TW (1) TW202233234A (https=)
WO (1) WO2022093724A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
DK4518970T3 (da) 2022-05-04 2026-04-07 Scholar Rock Inc Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation
WO2026076383A1 (en) 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
AU2008239606A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies

Also Published As

Publication number Publication date
EP4232151B1 (en) 2025-10-22
MX2023004763A (es) 2023-05-09
ES3058087T3 (en) 2026-03-06
PL4232151T3 (pl) 2026-02-23
AU2021369471A1 (en) 2023-06-15
EP4232151A1 (en) 2023-08-30
TW202233234A (zh) 2022-09-01
AU2021369471A9 (en) 2024-02-08
JP2023549455A (ja) 2023-11-27
CA3193909A1 (en) 2022-05-05
US20240002490A1 (en) 2024-01-04
KR20230095998A (ko) 2023-06-29
IL302132A (en) 2023-06-01
WO2022093724A1 (en) 2022-05-05
EP4729069A1 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
AU2021261907B2 (en) Use of myostatin inhibitors and combination therapies
CN116390756A (zh) 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途
CN119451696A (zh) 肌生成抑制蛋白抑制剂用于治疗脊髓性肌肉萎缩的用途
US20240358704A1 (en) Combined administration
EA051098B1 (ru) Применение антитела к промиостатину/латентному миостатину для лечения спинальной мышечной атрофии
WO2026076383A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
HK40097101A (en) Use of myostatin inhibitors and combination therapies
HK40043422A (en) Use of myostatin inhibitors and combination therapies
HK1260302A1 (en) Use of myostatin inhibitors and combination therapies
HK1260302B (en) Use of myostatin inhibitors and combination therapies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination